Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Immunotec, Lophius Ink Licensing Deals for Development of T-cell-based Assays

NEW YORK (GenomeWeb News) – Oxford Immunotec and Lophius Biosciences said today that they have signed agreements providing each other access to certain intellectual property.

As a result, Oxford Immunotec will be able to develop novel T-cell-based assays using Lophius' Urea technology and commercialize them in certain geographies. Lophius, which announced last week that it raised $5.3 million, can develop and commercialize novel T-cell-based assays under a license from Oxford Immunotec for its T-Spot technology.

Financial and other terms of the deals were not disclosed.

"We believe that Lophius' Urea technology has distinct advantages over conventional methods of designing and producing antigens for T-cell-based diagnostic systems," Peter Wrighton-Smith, CEO of Oxford Immunotec, said in a statement. "We are looking forward to combining Lophius' technology with our own, to develop and launch innovative new assays for infectious and immunological disease."

Based in Oxford, UK, Oxford Immunotec develops immunology-focused diagnostics. Lophius, headquartered in Regensburg, Germany, develops T-cell-based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.